Business
Harrow Launches Harrow Access for All (HAFA)
HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal
About this update from Harrow, Inc.
[{"type":"text","content":"HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All (“HAFA”), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All (“VAFA”) initiative, which launched in March 2025 with a strong reception from both physicians and patients. VAFA was designed to improve access and affordability to VEVYE® (cyclosporine ophthalmic solution) 0.1%, a prescription medication indicated for the treatment of the signs and symptoms of dry eye disease. By addressing cost and administrative barriers, VAFA quickly demonstrated the benefits of a patient-first, patient-focused access model, with VEVYE prescriptions growing 66% in the second quarter of 2025. HAFA now expands this proprietary patient access model from a single product to encompass Harrow’s comprehensive ophthalmic portfolio of branded, authorized generics (AGx), and compounded ophthalmic medications. Beginning in late 2025 and expanding into 2027, HAFA will provide a single, unified access point for prescribers and patients, offering affordability, streamlined prescribing, and predictable access. The platform creates a simpler, more predictable path to treatment—supporting better outcomes for patients and greater efficiency for physicians. “The launch of HAFA is the culmination of five years of work, which began in 2019 as we expanded beyond our market-leading ImprimisRx brand of compounded products, adding a portfolio of more than 15 branded ophthalmic products. We have always believed that our primary job is to serve eyecare professionals and provide what they need to offer optimal care for their patients. In line with this belief, HAFA will serve as the ‘Amazon for Ophthalmology’ – a seamless and unified platform, offering white-glove service that allows physicians to focus on patient care rather than managing paperwork, and dealing with pharmacy and pharmaceutical issues,” said Mark L. Baum, Chief Executive Offic...